Exclusive License Option Sample Clauses

Exclusive License Option. ARCH shall notify Licensee in writing ------------------------ in the event of termination of any prior license under any of the Licensed Patents. For a period of sixty (60) days from the date of such notice, Licensee shall have the right to negotiate with ARCH for an exclusive license under such Licensed Patents, on terms to be agreed upon by ARCH and
AutoNDA by SimpleDocs
Exclusive License Option. 2.9 University hereby grants to Licensee an exclusive option to negotiate with University for an exclusive license(s) to future University patent rights, technical information, know-how and biological materials developed outside of the Field of Use at the University by Xx. Xxxxxxx X.X Xxxx, alone or with collaborators, using funding administered through the University which is provided by agencies of the U.S. Government or by not-for-profit research foundations. Said exclusive option shall commence on the date that a U.S. patent application(s) is filed by the University on behalf of Xx. Xxxxxxx X.X. Xxxx alone or together with his collaborators and shall extend for a period of twelve (12) consecutive months beginning on the date of such patent filing. Licensee shall notify University in writing of Licensee’s intention to exercise its option prior to the date of expiration of the twelve (12) months option period. The Parties shall have six (6) months (extendible on mutual agreement of the parties) beginning on the date of Licensee’s written notice advising University of Licensee’s intent to exercise its option in which to negotiate and execute a license agreement with University.
Exclusive License Option. In addition to the license granted in Section 5.1, Institute grants Cisco an option to negotiate an exclusive license to the New Intellectual Property. Such option shall be exercisable in the following manner: Within thirty (30) days after Disclosure, as found in Section 3, Cisco shall notify Institute in writing if it wishes to exercise its option for any New Intellectual Property in the Disclosure. The parties shall negotiate a license agreement in good faith during a period not to exceed one hundred eighty (180) days from the date that Cisco exercises its option, or such period of time as the parties shall mutually agree. Institute will not, during the negotiation period, negotiate with any third party with a view to granting a license to, or assigning, the New Intellectual Property in the Disclosure. In addition, during the 12 months following the end of the negotiation period, Institute will not grant a license to or assign New Intellectual Property to any third party on any terms more favorable than those offered to Cisco pursuant to Section 5.2a). Any such exclusive license to New Intellectual Property granted by Institute to Cisco, as provided herein, shall include at least the following terms and conditions: the right of Cisco to grant sublicenses; a commitment by Cisco and any sublicensee to develop and commercialize the licensed invention and technology; a term that does not exceed any limits imposed by law; and retention by the Institute of the complete royalty-free right to use any New Intellectual Property for research or other educational purposes.
Exclusive License Option. Owner grants to Grantee an exclusive right and option (the “License Option”), which may be exercised at any time during the Option Period (as defined in Section 2 below), to obtain an exclusive license for access to and use of the Option Premises or any portion thereof and obtain certain easement and other rights over the remainder of the Property at reasonable times and upon reasonable notice for the purposes of designing, constructing, installing, inspecting, testing, owning, operating, monitoring, maintaining, repairing, removing and selling of electricity from a Fuel Cell Energy Facility (the “System”), substantially on the terms and conditions set forth in the attached PPA and License Agreement Term Sheet for the System attached hereto as Exhibit C and incorporated herein by this reference (the “Term Sheet”). As outlined in the Term Sheet, the PPA and License Agreement will include annual savings on the Owner’s electric bills [of approximately $ / at the equivalent of the fixed rate of $0. per kWh (which is $0. below the current effective rate)], over a term of no less than twenty (20) years. The activities which may be conducted pursuant to the Term Sheet are referred to hereinafter as “Fuel Cell Operations.”
Exclusive License Option. In the event that an Exclusive License is sold for Composition(s) outlined in this Non-Exclusive License contract, the terms agreed upon shall be upheld. In the event that the Licensee exceeds the total of granted unit copies or any other terms herein, an upgrade of the Non-Exclusive License or a re-negotiation for an Exclusive License may be possible, provided that Composition(s) has/have not been sold.
Exclusive License Option. Ionis hereby grants to Dynacure an option (the “Option”) to obtain the license set forth in Section 6.1. subject to this Article 4. Dynacure may exercise the Option at any time [***] following the date that Ionis delivers to Dynacure the Development Candidate Data Package (the “Option Deadline”). During such [***] period prior to the Option Deadline, Dynacure may request in writing additional data or information in Ionis’ possession relating to the Development Candidate.
Exclusive License Option 
AutoNDA by SimpleDocs

Related to Exclusive License Option

  • Exclusive License Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a sole and exclusive license under the Licensed Patent Rights in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer to sell, sell, and otherwise commercialize Licensed Product(s).

  • Exclusive License Grant Subject to the terms and conditions of this Agreement (including Section 3.5.1 (Takeda Retained Rights)), Takeda hereby grants to Licensee an exclusive, sublicensable (subject to Section 3.3 (Sublicensing)), royalty-bearing right and license under the Takeda Technology and Takeda’s interest in the Joint Technology to Exploit the Licensed Compounds and Licensed Products in the Field in the Licensee Territory.

  • Non-Exclusive License Grant In the event that either: (i) the making, have made or use by Merck or its Related Parties of any Cue Biologics during the term of this Agreement; or (ii) the making, having made, use, import, offer for sale and/or sale by Merck or its Related Parties of Compound or Product in the Territory would infringe a claim of an issued letters patent that Company (or its Affiliate) Controls and which patents are not covered by the grant in Section 3.1, Company hereby grants to Merck, to the extent Company is legally able to do so, a non-exclusive, sublicensable, royalty-free license in the Territory under such issued letters patent for Merck and its Related Parties to conduct such activities with respect to the Cue Biologics, Compounds and Products for all activities in the Field.

  • Non-Exclusive License Sponsor grants Institution and Principal Investigator a royalty free non-exclusive license, with no right to sublicense, to use Trial Data for internal research or educational purposes. c.

  • Grant of Exclusive License 1. Licensor hereby grants to Licensee an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.

  • Research License Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.

  • License Agreement The Trust shall have the non-exclusive right to use the name "Invesco" to designate any current or future series of shares only so long as Invesco Advisers, Inc. serves as investment manager or adviser to the Trust with respect to such series of shares.

  • Sublicense Rights Licensee shall not have the right to grant sublicenses under the licenses granted to it under Section 2.1(a) (Development and Commercialization License to Licensee) and Section 6.3(d) (Use of Coherus Trademark), without the prior written consent of Coherus, which consent may be withheld [***], except with respect to [***], in which case [***]. For the avoidance of doubt, it shall be [***] with respect to [***]. If Coherus consents in writing to allow Licensee to grant a sublicense, then Licensee may grant such sublicense, through [***], subject to the following: (a) each Sublicensee shall agree to be bound by all of the applicable terms and conditions of this Agreement; (b) the terms of each sublicense granted by Licensee shall provide that the Sublicensee shall be subject to the terms and conditions of this Agreement; (c) Licensee’s grant of any sublicense shall not relieve Licensee from any of its obligations under this Agreement; (d) Licensee shall be liable for any breach of a sublicense by a Sublicensee to the extent that such breach would constitute a breach of this Agreement, and any breach of the sublicense by such Sublicensee shall be deemed a breach of this Agreement by Licensee to the extent that such breach would constitute a breach of this Agreement as if Licensee had committed such breach; provided, however, that in each instance of any breach, Licensee and/or Sublicensee shall have the right to cure any such breach pursuant to the terms of this Agreement; and (e) Licensee will notify Coherus of the identity of any Sublicensee, and the territory in which it has granted such sublicense, promptly after entering into any sublicense. Notwithstanding anything to the contrary in this Agreement, for clarity, Licensee shall not have the right to grant sublicenses under Section 2.1 (License Grants) to any Third Party to Manufacture Products or to conduct Process Development.

  • Sublicense Grant Licensee will be entitled to grant Sublicenses to third parties under the license granted pursuant to Section 2.1 subject to the terms of this Section 2.3. Any such Sublicense shall be on terms and conditions in compliance with and not inconsistent with the terms of this Agreement. The grant of a Sublicense shall not in any way diminish or alter Licensee’s obligations under this Agreement.

  • LICENSE TERM The license term shall commence upon the License Effective Date, provided, however, that where an acceptance or trial period applies to the Product, the License Term shall be extended by the time period for testing, acceptance or trial.

Time is Money Join Law Insider Premium to draft better contracts faster.